August 2023

Latest Advancements in Antibody Engineering – Bispecifics, Diagnostic Controls, and More

2023-11-09T13:19:41-05:00August 29th, 2023|Webinars|

In this webinar, you will learn: Antibody technologies for the design of unique antibody formats Advancements in engineering efforts for the development of functionally tailored antibodies, recombinant isotype antibody panels, and multivalent fragment antibody constructs Characterization of different bispecific antibody formats Next generation protein sequencing to aid in bispecific antibody design [...]

July 2023

Antibody Discovery Dead Ends and New Approaches

2023-08-24T15:35:59-04:00July 20th, 2023|Webinars|

In this webinar, you will learn: About the challenges commonly encountered in antibody discovery campaigns, including non-functional antibodies, limited diversity, developability issues, and immunogenicity. How to de-risk antibody discovery campaigns, while balancing speed and spend Discover how a proteomics and mass spectrometry-based approach to antibody discovery, utilizing REpAb polyclonal sequencing, presents [...]

May 2023

Rational Antibody Design and Engineering with Next Generation Protein Sequencing

2023-11-09T13:21:24-05:00May 9th, 2023|Webinars|

In this webinar, you will learn: A strategy for generating recombinant mAbs and antibody derivatives directed towards antigens involved in mitotic cell division Methods for antibody engineering and customization, species switching, and construction of antibody fragments How Next Generation Protein Sequencing (NGPS) works Applications of NGPS to aid engineering and recombinant production of [...]

Secure Full Antibody and Target IP Protection with Next Generation Protein Sequencing

2023-06-21T10:20:38-04:00May 3rd, 2023|Articles|

Written by: Genya Gorshtein, MSc Published: April 21, 2023 Contents Introduction Target Specification for First Generation Antibodies Patent Strategies for Second-Generation Antibodies Next Generation Protein Sequencing and Proteomics Strengthens IP Protections Introduction Intellectual property (IP) protection is a critical step during the commercialization of antibodies [...]

April 2023

The Shortcut to Reliable Diagnostic, Control, and Assay Antibodies

2023-06-21T10:15:28-04:00April 5th, 2023|Webinars|

In this webinar, you will learn: IVD and immunoassays, supply chain risk management considerations How monoclonal and polyclonal antibody sequencing works, requirements Effective production, validation, and scale-up of recombinant antibody reagents Characterization of mAbs for assay design Abstract Polyclonal antibodies (pAbs) are well known for their robustness and [...]

Navigating Intellectual Property Protection for Antibodies

2023-06-21T10:21:38-04:00April 1st, 2023|Webinars|

In This Webinar, You Will Learn: Why IP is important in the development of antibody-based assets Patent application process and requirements How to strengthen patent applications Applications of Next Generation Protein Sequencing, SPR, and HDX-MS for antibody-related patent applications Abstract In the development of novel and innovative antibody-based [...]

February 2023

Therapeutic Antibody Discovery: From Target to Candidate

2023-06-21T10:23:33-04:00February 24th, 2023|Articles|

Written by: Genya Gorshtein, MSc Published: February 17, 2023 Contents Introduction Target Discovery and Validation Antibody Discovery Characterization and Lead Selection Engineering and Optimization Candidate Selection Therapeutic Antibody Discovery with Rapid Novor Introduction Monoclonal antibodies (mAbs) offer a vast range of configurations for therapeutic applications, [...]

Nanobody Lead Optimization with Epitope Mapping and Binning

2023-05-15T12:44:14-04:00February 14th, 2023|Webinars|

In this webinar, you will learn: How Rapid Novor’s de novo polyclonal sequencing platform REpAb® can accelerate any nanobody development pipeline How SPR and HDX-MS integrate into an antibody discovery and development workflow How to choose optimal lead candidates with SPR and HDX-MS How epitopes can be characterized using SPR and HDX-MS [...]

Towards Antigen-Specific Tregs for Type 1 Diabetes: Construction and Functional Assessment of Pancreatic Endocrine Marker, HPi2-Based Chimeric Antigen Receptor

2023-06-21T11:03:11-04:00February 3rd, 2023|Case Studies|

Antibodies with established, specific targets can be sequenced and utilized to engineer the hinge region and antigen-binding domains with antibody fragments and derivatives. With the sequence information in hand, further steps to optimizing a viable therapeutic approach can be more accessible.

December 2022

The Hunt for Novel Therapeutics Through Antibody Engineering

2023-06-21T10:25:09-04:00December 2nd, 2022|Articles|

Written by: Genya Gorshtein, MSc Published: November 1, 2022 Contents Introduction Approaches for Engineering Antibody Therapeutics Driving Antibody Engineering with Next Generation Protein Sequencing and Proteomics Introduction Antibody engineering encompasses various development, production strategies, and modification techniques to improve the biological properties of monoclonal antibodies (mAbs) [...]

Cell Specific Protein Degradation with Antibody Conjugated PROTACs

2023-05-25T10:29:24-04:00December 2nd, 2022|Articles|

Written by: Genya Gorshtein, MSc Published: November 25, 2022 Contents Introduction General PROTAC Structure and Function Antibody-Conjugated PROTACs Developing AbPROTACs with De Novo Antibody Sequencing and Proteomics Introduction Small-molecule drug development is aimed at inhibiting disease-promoting protein function through occupancy-driven protein inhibition. A major caveat of [...]

October 2022

Selecting Specific Monoclonal Antibodies by SPR – Alpaca Antibody Showdown

2023-05-15T12:44:34-04:00October 30th, 2022|Webinars|

In this SPR webinar, you will learn: How SPR works and its unique advantages for kinetic analysis of antibody-antigen interactions Applications of SPR in antibody discovery Functionality of SPR in antibody characterization Abstract Due to their ability to bind biomolecules specifically and tightly, antibodies are highly [...]

Resistance to Autosomal Dominant Alzheimer’s Disease in an APOE3 Christchurch Homozygote

2023-06-21T11:02:47-04:00October 21st, 2022|Case Studies|

De novo protein sequencing provided the research team with insurance by securing the complete amino acid sequence of a therapeutic mAb candidate for ADAD. This mass spectrometry-based protein sequencing technique can be used to obtain the sequence information of any antibody or protein for biomarker discovery, characterization, and validation. Access to this structural information only broadens our understanding of disease pathogenesis and fosters the development of innovative therapeutic or preventative treatments.

September 2022

Antibody-Drug Conjugates as Anti-Cancer Therapeutics

2023-05-25T10:30:00-04:00September 19th, 2022|Articles|

Written by: Genya Gorshtein, MSc Published: September 14, 2022 Contents Introduction ADCs as Novel Anti-Cancer Chemotherapeutics Key Components of ADCs Future Generation of ADCs De Novo Protein Sequencing Applications in ADC Development Introduction An antibody-drug conjugate (ADC) is a monoclonal antibody (mAb) with a covalently attached [...]

Characterizing Fragile Protein Complexes

2023-05-15T12:45:26-04:00September 14th, 2022|Webinars|

Webinar Highlights You will learn: Introduction to the structure and function of the tuberous sclerosis protein complex (pTSC) A novel strategy for isolating and purifying protein complexes from native sources using recombinantly produced Fabs How Next Generation Protein Sequencing (NGPS) works Applications of NGPS to aid design and engineering of recombinant antibody [...]

July 2022

Next Generation Vaccine Development with Proteomics

2023-06-21T11:01:12-04:00July 5th, 2022|Webinars|

As nearly all individuals have pre-existing immunity to influenza viruses, influenza-specific memory B cells will likely be recalled upon COBRA HA vaccination. By comparing the antibody response towards specific wild-type influenza strains and COBRA antigens, we can begin to understand the potential for COBRA-based vaccines to be used in the clinic.

June 2022

Characterization and Modulation of Anti-αβTCR Antibodies and Their Respective Binding Sites at the βTCR Chain to Enrich Engineered T Cells

2023-06-21T11:00:56-04:00June 17th, 2022|Case Studies|

αβTCR-engineered T cells have been applied in clinical trials, specifically directed against cancer/testis antigens. Though the clinical outcomes are promising, only a small proportion of patients benefit from these novel treatments. Lower response rates are partially attributed to a heterogeneous mixture of non-engineered and poorly engineered T cells that remain in the administered therapeutic product. For successful translation of these novel treatments into the clinic, engineering efforts should be reinforced with effective methods for engineered T cell purification and engineered T cell elimination post infusion into patients.

May 2022

Enriching Engineered T Cells with Antibody Sequencing & Modulation

2023-06-21T10:59:48-04:00May 10th, 2022|Webinars|

Known, high-performing and well used antibodies against useful targets on CAR-T cells can be examined for mechanism of action using proteomics and mass spectrometry. Knowledge of the antibody sequences via Next Generation Protein Sequencing (NGPS) can be useful for humanizing or otherwise engineering constructs. Rapid Epitope mapping by HDX can be useful for both epitope and paratope engineering strategies.

April 2022

Broadly Neutralizing Antibody Cocktails Targeting Nipah Virus and Hendra Virus Fusion Glycoproteins

2023-06-21T10:18:26-04:00April 29th, 2022|Case Studies|

Hendra virus (HeV) and Nipah virus (NiV) are types of Henipaviruses (HNVs) that originated in bats and can infect the human respiratory system with detrimental consequences. As enveloped, single-stranded RNA viruses, HeV and NiV use attachment (G) and fusion (F) glycoproteins on the envelope membrane to enter host cells. So far, there are no approved therapeutics or vaccines to combat the viruses in humans.

Generation and Diversification of Recombinant Monoclonal Antibodies

2023-06-21T10:54:12-04:00April 22nd, 2022|Case Studies|

Monoclonal antibodies are essential reagents and research tools. They are commonly generated and produced in hybridoma cells and are expected to be highly consistent. However, the instability and fragility of hybridoma cells can cause unwanted mutations, additional chains, and permanent loss of important antibodies. On the other hand, the lack of standardization validation for commercial antibodies often keeps researchers in the dark leading to the reproducibility crisis. 

March 2022

First Immunoassay for Measuring Isoaspartate in Human Serum Albumin

2023-06-21T10:52:50-04:00March 25th, 2022|Case Studies|

The ongoing pandemic has reinforced the need for in vitro diagnostics to globally surveille emerging pathogens and provide better medical care. In particular, immunoassays are favoured due to their affordability, ease, and speed. Nevertheless, the combination of rapidly evolving pathogens, and more complex diseases resulting from increasing life expectancy worldwide require more sensitive and specific immunoassays in the nick of time. To increase sensitivity, immunoassay development can benefit from exploiting industry-leading technologies such as de novo protein sequencing.

February 2022

December 2021

Polyclonal Antibody Sequencing in Therapeutics Development Pipelines

2023-06-21T10:58:31-04:00December 20th, 2021|Webinars|

Over the past several years Rapid Novor has been developing the world's best antibody protein sequencing platform, with over 2700 monoclonal antibodies and proteins sequenced. In 2020, they unveiled their most advanced technology to date- REpAb® polyclonal antibody sequencing. The platform combines the world's best protein sequencing technology and NGS to comprehensively mine the antigen specific antibody repertoire present in rabbit and human patient samples. By leveraging the platform, teams can build robust antibody assays and therapeutic leads derived from patient's blood.

Next Generation Protein Sequencing in Veterinary Medicine and Industry

2023-05-15T12:31:25-04:00December 3rd, 2021|Whitepapers|

Since 2006, the One Health Initiative (OHI)’s goal has been to demonstrate the inextricable link between humans, animals, and the environment. Certainly, the current global pandemic is a great testament to the ties between climate change, humans, and animals that OHI has been working to highlight. The rise of other zoonotic diseases (e.g., Hendra, and Nipah viruses) not only directly affect humans through disease transmission but may also result in deep impacts to the food supply

November 2021

October 2021

Ushering the New Era in Anti-Drug Antibody Assays with Next Generation Protein Sequencing

2023-05-15T12:31:01-04:00October 15th, 2021|Whitepapers|

Anti-drug antibody (ADA) assays are critical to assess the clinical efficacy and safety of a biological drug and rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived pooled polyclonal antibodies or human monoclonal antibody reference panels against the target protein drug.

September 2021

August 2021

Antibody Validation and its Use Cases

2023-05-15T11:43:28-04:00August 4th, 2021|Articles|

Antibodies are used in a variety of ways in academia and industry, from tools to therapeutics. Because antibodies are produced using live processes, which are naturally error-prone, validation is required from time to time. Furthermore, to develop biological therapeutics, the protein sequence must be confirmed as part of the regulatory process.

July 2021

June 2021

Bispecific Therapeutics Explained

2023-05-15T11:55:16-04:00June 28th, 2021|Articles|

Bispecific therapeutics are monoclonal antibodies that carry a specific antigen-binding capability on each arm. Bispecifics are thus capable of having two specificities that can either double the binding affinity of the antibody toward the same antigen (increased avidity), or can now bind to two targets. Bispecifics are most often described as two types: trispecifics and bispecific T-cell engaged antibodies (BiTE).

Major Antibody Databases and Their Applications

2023-05-15T11:56:11-04:00June 18th, 2021|Articles|

Written by María Gerpe, PhD June 18, 2021 Introduction Research publications represent an additional source of validation proof for commercially available antibodies. As such, academic and industry scientists often also rely on publication references to decide which commercial antibody to purchase. Several independent efforts exist to compile such information. For instance, [...]

March 2021

The Underlying Cause of Medical Diagnostic Invalidation

2023-05-15T12:40:02-04:00March 23rd, 2021|Whitepapers|

In-vitro diagnostics (IVDs) are one of the most commonly used tools to diagnose conditions and guide treatment decisions and are often considered the “silent champion” of healthcare. They work by detecting the absence or presence of particular markers or by measuring the concentration of analytes or specific substances.

November 2020

September 2020

Leveraging Recombinant Patient Antibodies in Therapeutic Applications

2023-06-21T10:54:56-04:00September 3rd, 2020|Webinars|

Our team has perfected the art of monoclonal antibody sequencing and is now ready to demonstrate our ability to sequence mAbs from polyclonal mixtures. In this talk, Anthony will walk through our new polyclonal sequencing platform that uses both proteomics and genomics to sequence the most abundant antibodies found in polyclonal sera.

June 2016

Moving Towards Recombinant Monoclonal Antibodies

2023-05-15T11:59:37-04:00June 30th, 2016|Articles|

Recombinant Monoclonal Antibodies (rAbs) are highly reproducible, customizable and pure alternatives to the traditional antibodies produced by hybridomas. Get the antibody protein sequence, either by DNA sequencing or the de novo protein sequencing technology, you can rest assured that you can have the exact antibody made recombinantly anytime in the future.